CTOR (Citius Oncology) NonCurrent Deferred Liabilities: $2.82 Mil (As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.68
! 2 Warning Signs
View Full Analysis

What is Citius Oncology NonCurrent Deferred Liabilities?

Citius Oncology CTOR -2.10% 10 NonCurrent Deferred Liabilities is $2.82 Mil as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Citius Oncology's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $2.82 Mil.

Citius Oncology NonCurrent Deferred Liabilities Related Terms

Citius Oncology NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Citius Oncology's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology NonCurrent Deferred Liabilities Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
NonCurrent Deferred Liabilities
0.58 1.15 1.73 2.79

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 2.52 2.79 3.05 2.82
CTOR
10GF Score
Citius Oncology Inc CTOR
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $2.82 Mil mean?
Citius Oncology (CTOR) has a NonCurrent Deferred Liabilities of $2.82 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Citius Oncology and its competitors.
Is Citius Oncology's NonCurrent Deferred Liabilities too high?
Citius Oncology's current NonCurrent Deferred Liabilities is $2.82 Mil. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's NonCurrent Deferred Liabilities compare to INCR and TLPH?
Citius Oncology's NonCurrent Deferred Liabilities of $2.82 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Citius Oncology and its competitors. Citius Oncology's current NonCurrent Deferred Liabilities is $2.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current NonCurrent Deferred Liabilities of $2.82 Mil. The current NonCurrent Deferred Liabilities is $2.82 Mil. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Citius Oncology (CTOR), the current NonCurrent Deferred Liabilities is $2.82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price